Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Trellus Health PLC ( (GB:TRLS) ) has shared an update.
Trellus Health plans to raise up to £5 million via a 12‑month secured convertible loan note facility from an institutional investor, with warrants attached and funds available in staged tranches, subject to shareholder approval at a general meeting on 20 January 2026. The financing is designed to extend the company’s cash runway, with the first two tranches expected to fund operations until late Q1 2026, support ongoing commercial initiatives and partnership discussions, and provide flexibility over the timing and scale of capital drawdowns, but the board warns that failure to secure shareholder backing or alternative funding would likely result in the company ceasing to be a going concern and entering administration.
More about Trellus Health PLC
Trellus Health plc is a UK AIM-quoted healthcare company focused on digital health solutions for complex chronic conditions. Its core product, Trellus Elevate®, is a proprietary resilience-based digital platform that integrates data analytics with personalised, scientifically validated self‑management and support programmes. Initially targeting inflammatory bowel disease and other high‑cost gastrointestinal disorders, the platform has demonstrated substantial reductions in hospitalisations and emergency room visits, and is being commercialised across pharmaceutical patient support programmes, clinical trial recruitment and retention services, and partnerships with US health plans.
Average Trading Volume: 490,784
Technical Sentiment Signal: Sell
Current Market Cap: £888.3K
See more data about TRLS stock on TipRanks’ Stock Analysis page.